Icon plc

ICON acquires HumanFirst, a cloud-based technology company for life sciences supporting precision measurement in patient centred clinical research. ICON provides full service outsourcing and flexible support for biotech specific needs such icon plc due diligence and asset valuation. Advancements in Artificial Intelligence for site selection Using human-enabled AI to enhance decision-making and minimise risk Read the whitepaper. A multifaceted risk factor: Addressing obesity's impact across the disease spectrum Read the whitepaper, icon plc.

Powered by. It provides specialized services that span the entire lifecycle of product development. Bolster business development with timely opportunities. Review investigator profiles and find information on trial contacts across ICON Plc, including performance indicators like number of completed trials, and linked attributes such as rehiring statistics. Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content. History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events. Have you found what you were looking for?

Icon plc

ICON plc is an Irish headquartered Nasdaq listed multinational healthcare intelligence and clinical research organisation that provides consulting, clinical development and commercialisation services for the pharmaceutical industry. Lambe retired from the board of directors in Contents move to sidebar hide. Article Talk. Read Edit View history. Tools Tools. Download as PDF Printable version. See also: Icon disambiguation. Irish pharmaceutical company. Traded as.

History section provides information on new products, icon plc, mergers, acquisitions, expansions, approvals, and many more icon plc events. Article Talk. Contact the team or request a demo to find out how our data can drive your business forward.

.

The new ICON will have a renewed focus on leveraging data, applying technology and accessing diverse patient populations to speed up drug development. ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland , ICON will operate from locations in 47 countries and have approximately 38, employees as of July 1, This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, the impact of COVID on our business, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions.

Icon plc

CEO Dr. Our world class team aided in the development of 30 customer drug and device approvals in the year, including breakthrough COVID vaccines and therapies. Additionally, a number of discussions have continued with customers contemplating an expanded or new strategic relationship with ICON, as the increased scale, innovative solutions and best in class performance of new ICON address unmet industry needs. This represents a year on year increase of In addition to the financial measures prepared in accordance with generally accepted accounting principles GAAP , this press release contains certain non-GAAP financial measures, including adjusted revenue, adjusted EBITDA, adjusted net income attributable to the Group and adjusted diluted earnings per share attributable to the Group.

2013 maserati granturismo review

History History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events. DOCS Global. Irish pharmaceutical company. Crosstree Capital. Optimising biotech funding whitepaper series Read the whitepapers. Retrieved 8 December The Irish Times. In September, the company entered into a partnership with the U. Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content. Early Clinical and Bioanalytical Solutions Innovative early clinical solutions that will advance your drug development strategy. Register now. Retrieved

Following a comprehensive review of study start-up activities, ICON has adopted a range of new processes and procedures that have streamlined site activation.

Contract research organization. Early Clinical and Bioanalytical Solutions Innovative early clinical solutions that will advance your drug development strategy. Market Screener. In September, the company entered into a partnership with the U. Securities and Exchange Commission. Retrieved Dismiss Search Modal. History History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events. Pharma Times. Biotech ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation. Retrieved 19 February Health Economics. Contents move to sidebar hide.